Chicago Islet Consortium ICR at UIC

UIC 的芝加哥小岛联盟 ICR

• 批准号: 7501060
• 负责人: Jose Oberholzer
• 金额: $ 4.73万
• 依托单位: UNIVERSITY OF ILLINOIS AT CHICAGO
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-09-30 至 2009-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7501060
• 关键词: Accounting; Address; American; Antioxidants; Arts; Biopsy; Bioreactors; Blindness; Blood Glucose; Cardiovascular Diseases; Cell Therapy; Cell Transplantation; Cells; Centrifugation; Chicago; Chronic; Clinical; Clinical Protocols; Collaborations; Collection; Communities; Complex; Core Facility; Development; Diabetes Mellitus; Endocrine; Failure; Freedom; Funding; Glucose; Glutamine; Hemoglobin; Hormones; Human; Hypoglycemia; Hypoglycemic Agents; Illinois; Incubators; Infusion procedures; Institution; Insulin; Insulin-Dependent Diabetes Mellitus; International; Islet Cell; Islets of Langerhans; Islets of Langerhans Transplantation; Italy; Kidney Failure; Laboratories; Laboratory Study; Medicine; Methods; Numbers; Oxidative Stress; Oxygen; Pancreas; Patients; Phase; Practice Guidelines; Predictive Factor; Predictive Value; Preparation; Procedures; Process; Production; Purpose; Quality Control; Recovery of Function; Replacement Therapy; Research; Research Personnel; Resources; Shipping; Ships; Source; Techniques; Testing; Texas; Transplantation; Transportation; United States Food and Drug Administration; Universities; Warm Ischemia; base; blood glucose regulation; cell preparation; clinical application; college; diabetic; flasks; improved; in vivo; islet; neuronal cell body; prevent; programs; research and development; type I diabetic

Type I diabetes results from the body's failure to produce insulin, the hormone that "unlocks" the cells of the body, allowing glucose to enter and fuel them. It is estimated that 20.8 Million Americans have diabetes; type I diabetes accounts for 5 to 10%of cases (approximately 1.56 Million type I diabetic patients). Keeping blood glucose levels under tight control represents the most effective way either to prevent the onset or to reduce the progression of the chronic complications of type I diabetes, such as blindness, kidney failure and cardiovascular diseases. Islet transplantation can achieve insulin independence, glucose control and freedom of hypoglycemic attacks in patients afflicted with Type I diabetes mellitus. However, the recovery of functional pancreatic islets from cadaveric donor pancreata is a complex procedure and needs to be optimized. Until an unlimited source of human pancreatic islet cell becomes available, the further development of endocrine replacement therapy for the treatment of diabetes will solely depend on the availability of high quality islet preparations, both for clinical application and laboratory-based research. Because of the complexity of the islet isolation procedure, it would be desirable to concentrate the know-how in a limited number of centers or consortiums to allow for optimal use of available resources. The aim of this application is to extend the existing human islet core facility at the University of Illinois and the Chicago Islet Consortium into a federally funded Islet Cell Resource Center to isolate, purify, characterize and distribute human pancreatic islet cells for both transplantation into diabetic patients and use in laboratory studies to a larger community. The ICR at UIC with its partners in the Chicago Islet Consortium will be responsible for the procurement of whole pancreata, isolation and quality control of islet cell preparations, and distribution of islets for approved research or clinical protocols. The ICR at UIC is conducting research and development to improve isolation techniques, cellular viability and function, and shipping procedures, and is investigating methods for improved assessment of islet mass, composition, quality and viability. In addition, and most importantly for the progres of the field, the ICR at UIC will continue to provide large numbers of high-quality islet preparations for transplantation in diabetic patients.

I型糖尿病是由于人体未能产生胰岛素的糖尿病而引起的，这种激素“解锁”了细胞的细胞 身体，使葡萄糖进入并加油。据估计，有2080万美国人患有糖尿病。 I型糖尿病占病例的5％至10％（约15.6万I型糖尿病患者）。保持 严格控制下的血糖水平是防止发作或进行的最有效方法 减少I型糖尿病的慢性并发症的进展，例如失明，肾衰竭和 心血管疾病。胰岛移植可以实现胰岛素独立性，葡萄糖控制和 患有I型糖尿病的患者的降血糖发作自由。但是，恢复 来自尸体供体胰腺的功能性胰岛是一个复杂的过程，需要是 优化。直到无限的人类胰岛胰岛细胞可用， 内分泌替代疗法的开发以治疗糖尿病，将仅取决于 用于临床应用和基于实验室的研究的高质量胰岛制备的可用性。 由于胰岛隔离程序的复杂性，因此希望集中专业知识 在有限数量的中心或财团中，可以最佳地使用可用资源。 该应用的目的是扩展伊利诺伊大学现有的人类胰岛核心设施， 芝加哥胰岛财团成为一个由联邦资助的小岛电池资源中心，以隔离，净化， 表征和分配人类胰岛细胞，以将两种移植到糖尿病患者中并使用 在实验室研究中，向更大的社区进行研究。 UIC的ICR及其在芝加哥小岛财团的合作伙伴 将负责整个胰腺的采购，胰岛细胞的隔离和质量控制 用于批准的研究或临床方案的胰岛的准备和分布。 UIC的ICR是 进行研发以改善隔离技术，细胞活力和功能以及 运输程序，并正在调查改进胰岛质量，组成的评估的方法 质量和生存能力。 此外，最重要的是，对于该领域的前进，UIC的ICR将继续提供大型 糖尿病患者移植的高质量胰岛制剂数量。

项目成果

Five-year follow-up of patients with type 1 diabetes transplanted with allogeneic islets: the UIC experience.

• DOI: 10.1007/s00592-014-0627-6
• 发表时间: 2014-10
• 期刊: Acta diabetologica
• 影响因子: 3.8
• 作者: Qi M;Kinzer K;Danielson KK;Martellotto J;Barbaro B;Wang Y;Bui JT;Gaba RC;Knuttinen G;Garcia-Roca R;Tzvetanov I;Heitman A;Davis M;McGarrigle JJ;Benedetti E;Oberholzer J
• 通讯作者: Oberholzer J

Systematic prevention of bubble formation and accumulation for long-term culture of pancreatic islet cells in microfluidic device.

• DOI: 10.1007/s10544-011-9618-3
• 发表时间: 2012-04
• 期刊: BIOMEDICAL MICRODEVICES
• 影响因子: 2.8
• 作者: Wang, Yong;Lee, Dongyoung;Zhang, Lisa;Jeon, Hyojin;Mendoza-Elias, Joshua E.;Harvat, Tricia A.;Hassan, Sarah Z.;Zhou, Amanda;Eddington, David T.;Oberholzer, Jose
• 通讯作者: Oberholzer, Jose

Survival of human islets in microbeads containing high guluronic acid alginate crosslinked with Ca2+ and Ba2+.

• DOI: 10.1111/xen.12009
• 发表时间: 2012-11
• 期刊: Xenotransplantation
• 影响因子: 3.9
• 作者: Qi M;Mørch Y;Lacík I;Formo K;Marchese E;Wang Y;Danielson KK;Kinzer K;Wang S;Barbaro B;Kolláriková G;Chorvát D Jr;Hunkeler D;Skjåk-Braek G;Oberholzer J;Strand BL
• 通讯作者: Strand BL

Impairment of neurovascular coupling in Type 1 Diabetes Mellitus in rats is prevented by pancreatic islet transplantation and reversed by a semi-selective PKC inhibitor.

• DOI: 10.1016/j.brainres.2016.11.012
• 发表时间: 2017-01-15
• 期刊: Brain research
• 影响因子: 2.9
• 作者: Vetri F;Qi M;Xu H;Oberholzer J;Paisansathan C
• 通讯作者: Paisansathan C

A multi-parametric islet perifusion system within a microfluidic perifusion device.

微流体灌注装置内的多参数胰岛灌注系统。

• DOI: 10.3791/1649
• 发表时间: 2010
• 期刊: Journal of visualized experiments : JoVE
• 作者: Adewola,AdeolaF;Wang,Yong;Harvat,Tricia;Eddington,DavidT;Lee,Dongyoung;Oberholzer,Jose
• 通讯作者: Oberholzer,Jose